Evidence map›Paper›PMID 35464182›Full record

ArticleF1000Research2021

Case Report: Therapeutic and immunomodulatory effects of plasmapheresis in long-haul COVID.

Dobri D Kiprov, Ahvie Herskowitz, Daehwan Kim, Michael Lieb, Chao Liu, Etsuko Watanabe, Jan C Hoffman, Regina Rohe, Michael J Conboy, Irina M Conboy

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in F1000Research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dobri D KiprovCalifornia Medical Pacific Center, San Francisco, CA, 94109, USA.
Ahvie HerskowitzCalifornia Medical Pacific Center, San Francisco, CA, 94109, USA.
Daehwan KimBioengineering, UC Berkeley, Berkeley, CA, 94720, USA.ORCID 0000-0002-7273-9969
Michael LiebBioengineering, UC Berkeley, Berkeley, CA, 94720, USA.
Chao LiuBioengineering, UC Berkeley, Berkeley, CA, 94720, USA.ORCID 0000-0001-8683-3473
Etsuko WatanabeBioengineering, UC Berkeley, Berkeley, CA, 94720, USA.
Jan C HoffmanDepartment of Laboratory Medicine, UCSF, San Francisco, CA, San Francisco, USA.
Regina RoheCalifornia Medical Pacific Center, San Francisco, CA, 94109, USA.
Michael J ConboyBioengineering, UC Berkeley, Berkeley, CA, 94720, USA.
Irina M ConboyBioengineering, UC Berkeley, Berkeley, CA, 94720, USA.ORCID 0000-0002-4276-0644
University of California, Berkeley · USCalifornia Pacific Medical Center · US

Funding

Identifying signatures of brain aging through heterochronic blood exchangeR01AG071787 · NIA · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI MESSERSMITH, PHILLIP B, MOURRAIN, PHILIPPE · 2021 to 2025
$2.3M
New Generation Blood Exchange Devices for Enhancing Tissue Regeneration and HealthR01HL139605 · NHLBI · UNIVERSITY OF CALIFORNIA BERKELEY · PI ARAN, KIANA, CONBOY, IRINA M · 2018 to 2021
$1.6M
Treatment of Duchenne Muscular Dystrophy with Cas9 Protein Complexed to Gold NanoparticlesR01EB023776 · NIBIB · UNIVERSITY OF CALIFORNIA BERKELEY · PI CONBOY, IRINA M, MURTHY, NIREN · 2017 to 2020
$1.4M
Defined pharmacology for multi-tissue rejuvenation acting through youthful normalization of p16R56AG058819 · NIA · UNIVERSITY OF CALIFORNIA BERKELEY · PI CONBOY, IRINA M · 2018 to 2018
$381k
NHLBI NIH HHS R01 HL139605NIA NIH HHS R01 AG071787NIA NIH HHS R56 AG058819NIBIB NIH HHS R01 EB023776
6 · The paper itself

Abstract

Many patients with COVID-19 experience a range of debilitating symptoms months after being infected, a syndrome termed long-haul COVID. A 68-year-old male presented with lung opacity, fatigue, physical and cognitive weaknesses, loss of smell and lymphocytopenia. After rounds of therapeutic plasma exchange (TPE), the patient returned to normal activities and work. Mechanistically in the patient's peripheral blood mononuclear cells (PBMCs), markers of inflammatory macrophages diminished and markers of lymphocytes, including natural killer (NK) cells and cytotoxic CD8 T-cells, increased. Circulating inflammatory proteins diminished, while positive regulators of tissue repair increased. This case study suggests that TPE has the capacity to treat long-haul COVID.

Indexed as

COVID-19AgedHumansLeukocytes, MononuclearMalePlasma ExchangePlasmapheresisPost-Acute COVID-19 Syndromeadaptive immunityImmunomodulationinflammationleukocyute subsetsLong Haul Covid19plasmapheresisproteomics

Identifiers

PMID35464182
PMCPMC9021669.2
OpenAlexW4226250009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.